



NZX/ASX Announcement

28 May 2026

TruScreen appoints Uzbekistan distributor and commences pilot clinical study

- **Albatros Health Care LLC appointed as Uzbekistan distributor**
- **Sales revenue potential is USD740,000 (NZD1.26m) to the end of 2028**
- **Approval for commencement of c600 patient pilot clinical study in Tashkent, Uzbekistan expected by early June 2026**
- **Study results to provide validation data to support TruScreen use nationally, in public and private healthcare settings**

TruScreen Group Limited (NZX/ASX: TRU) (TruScreen or the Company), a global leader in AI-enabled cervical cancer screening, is pleased to announce the appointment of Albatros Health Care LLC as its distributor in Uzbekistan and the commencement of a pilot clinical study in Tashkent to support market entry.

Uzbekistan distributor appointed

TruScreen appointed Albatros Health Care LLC on 18 May 2026.

Albatros is an Uzbek medical device distributor established in 2017 that provides modern medical technologies into Uzbekistan. It has a nationwide sales network and works closely with government stakeholders.

Sales revenue potential is USD740,000 (NZD1.26m) over the 30-month period to the end of 2028. The first batch of TruScreen screening devices was shipped this week to Uzbekistan to support launch activities, training and the pilot clinical study in Tashkent.

Pilot clinical study in Tashkent

A pilot clinical study will commence following ethics approval received in May 2026. The study will be conducted at Obstet Gynecol Clinic in Tashkent and will enrol approximately 600 participants over a month.

As per the Memorandum of Understanding signed in August 2025, the objectives of the program are:

1. To assess cervical screening options for the women of Uzbekistan and the implementation of TruScreen in the most effective way to prevent cervical cancer deaths, and to determine the accuracy, reliability and operational requirements of TruScreen compared to Pap smear in detecting early cancerous changes in the cervix.
2. To develop a National Cervical Cancer Screening program for Uzbekistan



The clinical study results are expected to provide validation data for TruScreen to support use in both public and private healthcare settings in Uzbekistan. The country has 11.32 million women of screening age*, and cervical cancer ranks as the second most frequent cancer among women, providing significant growth opportunity for reduction in cervical cancer deaths.

The study will be led by Dr Pakhomova as principal investigator, with Dr Klara Yadgorava acting as advisor overseeing the project. Dr Yadgorava is a World Health Organization national consultant for Uzbekistan and a consultant for Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH (a German based global NGO) on Uzbekistan projects.

Training and launch support

Senior TruScreen clinical managers will support the pilot project and the launch of TruScreen in Uzbekistan, in July 2026. The training program is intended to support both clinical users of the TruScreen device and the Albatros sales team ahead of broader commercial rollout.

Strategic significance

Uzbekistan is a significant market and a regional healthcare centre for neighbouring Central Asian “Stans” nations where TruScreen’s innovative, real-time technology would be equally well-suited for public screening adoption.

TruScreen’s market expansion is accelerating through increasing recognition from healthcare professionals, governments and NGOs as a solution to the challenges of conducting public cervical cancer screening programs in emerging markets. TruScreen is in advanced discussions with potential distributors in several additional countries, consistent with its strategy of expanding through capable local partners in key emerging markets.

Executive Chairman Tony Ho said:

“We are pleased to appoint Albatros Health Care as TruScreen’s distributor in Uzbekistan and to commence this important pilot clinical study in Tashkent. Uzbekistan represents a compelling market opportunity, and we believe TruScreen’s real-time, AI-enabled cervical cancer screening technology is well suited to local screening needs, particularly where scalable public screening solutions are required.

The pilot study will generate valuable local data to support broader adoption in both the public and private sectors. Together with Albatros’ nationwide network and government relationships, this initiative provides a strong platform for TruScreen’s growth in Uzbekistan and the wider Central Asian region.”

This announcement has been approved by the Board.

* Female population ages 15-64, Source: World Population Prospects, United Nations Population Division, World Bank



For more information, visit
www.truscreen.com
or contact:

TruScreen Group Limited
Tony Ho
Executive Chairman
info@truscreen.com

About TruScreen

TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand and Australian listed company with a real-time, AI-enabled cervical cancer screening technology designed to detect pre-cancerous and cancerous changes of the cervix.

The TruScreen device is registered for use in multiple markets and has been used to screen more than 1,000,000 women worldwide.

TruScreen's technology is designed to support cervical cancer screening in settings where access to laboratory infrastructure and specialist pathology services may be limited, making it well suited to emerging markets and public screening initiatives.